ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

MAVYRET
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

MAVYRET Rx

Generic Name and Formulations:
Glecaprevir, pibrentasvir 100mg/40mg; tabs.

Company:
AbbVie

Therapeutic Use:

RECENT UPDATES

Monograph added.

Indications for MAVYRET:

Chronic HCV genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. HCV genotype 1 infection in adults previously treated with an HCV NS5A inhibitor- or NS3/4A protease inhibitor-containing regimen, but not both.

Adult:

Test for HBV infection prior to initiation. Take with food. ≥18yrs: 3 tabs once daily. Treatment-naive: treat for 8 weeks (no cirrhosis) or 12 weeks (compensated cirrhosis). Treatment-experienced (genotype 1): treat for 16 weeks if previously treated with an NS5A inhibitor (without prior NS3/4A protease inhibitor) or for 12 weeks if previously treated with an NS3/4A protease inhibitor (without prior NS5A inhibitor); (genotypes 1, 2, 4, 5, 6): treat for 8 weeks (no cirrhosis) or 12 weeks (compensated cirrhosis) if previously treated with regimens containing IFN, PEG-IFN, ribavirin, and/or sofosbuvir, but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks (with or without compensated cirrhosis) if previously treated with regimens containing IFN, PEG-IFN, ribavirin, and/or sofosbuvir, but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor. HCV/HIV-1 co-infected with or without compensated liver disease or renal impairment including on hemodialysis: follow same dosage regimen. See full labeling.

Children:

<18yrs: not established.

Contraindications:

Severe hepatic impairment (Child-Pugh C). Concomitant atazanavir or rifampin.

Warnings/Precautions:

Risk of HBV reactivation in patients coinfected with HCV/HBV. Test all patients for HBV infection by measuring HBsAg and anti-HBc; if positive serologic evidence, monitor for hepatitis flare or HBV reactivation during and at post-treatment follow-up; treat if clinically indicated. Moderate hepatic impairment (Child-Pugh B): not recommended. Pregnancy. Nursing mothers.

Interactions:

See Contraindications. Concomitant certain immunosuppressants or chemotherapeutic agents: may increase risk of HBV reactivation. May be antagonized by P-gp/CYP3A inducers (eg, carbamazepine, efavirenz, St. John's wort); concomitant use not recommended. May increase risk of ALT elevations with concomitant ethinyl estradiol-containing drugs (eg, combined oral contraceptives): not recommended. Concomitant darunavir, lopinavir, ritonavir: not recommended. Concomitant dabigatran etexilate; refer to its prescribing information for dose modification. Potentiates digoxin (reduce dose by ½); monitor. Concomitant use may potentiate atorvastatin, lovastatin, simvastatin: not recommended. May potentiate pravastatin (reduce dose by ½), rosuvastatin (limit max dose at 10mg), fluvastatin, or pitavastatin (use lowest effective dose of both these drugs). Patients requiring cyclosporine doses >100mg/day: not recommended.

Pharmacological Class:

HCV NS3/4A protease inhibitor + HCV NS5A inhibitor.

Adverse Reactions:

Headache, fatigue, serum bilirubin elevations; HBV reactivation.

Generic Availability:

NO

How Supplied:

Carton—4-Week, 8-Week

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs